EBT-107

EBT-107 is a CRISPR-based gene therapy developed by Excision BioTherapeutics for the treatment of chronic hepatitis B virus (HBV) infection. It utilizes a dual-guide RNA system delivered via lipid nanoparticles to target and excise large sections of HBV DNA, including both episomal and integrated forms, from infected liver cells. This approach aims to eliminate covalently closed circular DNA (cccDNA), which is responsible for persistent HBV infection and is not addressed by current antiviral therapies. Preclinical studies have demonstrated that EBT-107 can achieve rapid reductions in viral biomarkers (such as HBV DNA, HBsAg, and HBeAg) with minimal off-target effects or chromosomal aberrations. The technology underlying EBT-107 was licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University[1][3][4][5][6][7][8].